Hospira Dacarbazine for Injection 600 mg/ vial

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

dacarbazine, Quantity: 600 mg

Disponibbli minn:

Hospira Australia Pty Ltd

INN (Isem Internazzjonali):

Dacarbazine

Għamla farmaċewtika:

Injection, powder for

Kompożizzjoni:

Excipient Ingredients: citric acid monohydrate; mannitol; sodium hydroxide

Rotta amministrattiva:

Intravenous

Unitajiet fil-pakkett:

1 x 100 mL vial

Klassi:

Medicine Listed (Export Only)

Tip ta 'preskrizzjoni:

Not scheduled. Not considered by committee

Indikazzjonijiet terapewtiċi:

Dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Dacarbazine is used as part of combination chemotherapy for the treatment of advanced Hodgkin's disease, advanced adult soft tissue sarcomas (except mesothelioma and Kaposi sarcoma). Dacarbazine has been shown, when used in combination with other cytotoxic agents, to be of use in the treatment of other malignant diseases including carcinoma of the colon, ovary, breast, lung, testicular teratoma, and solid tumours in children.

Sommarju tal-prodott:

Visual Identification: A white or very pale yellow powder or plug; Container Type: Vial; Container Life Time: 18 Months

L-istatus ta 'awtorizzazzjoni:

Listed (Export Only)

Data ta 'l-awtorizzazzjoni:

2006-03-10